These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 3302713

  • 1. Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity.
    Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S.
    N Engl J Med; 1987 Aug 27; 317(9):550-6. PubMed ID: 3302713
    [Abstract] [Full Text] [Related]

  • 2. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes.
    Soumerai SB, Ross-Degnan D, Avorn J, McLaughlin Tj, Choodnovskiy I.
    N Engl J Med; 1991 Oct 10; 325(15):1072-7. PubMed ID: 1891009
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Unintended outcomes of medicaid drug cost-containment policies on the chronically mentally ill.
    Soumerai S.
    J Clin Psychiatry; 2003 Oct 10; 64 Suppl 17():19-22. PubMed ID: 14680423
    [Abstract] [Full Text] [Related]

  • 6. Effect of copayments on drug use in the presence of annual payment limits.
    Kephart G, Skedgel C, Sketris I, Grootendorst P, Hoar J.
    Am J Manag Care; 2007 Jun 10; 13(6 Pt 2):328-34. PubMed ID: 17567233
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Trends in prescription drug expenditures by Medicaid enrollees.
    Banthin JS, Miller GE.
    Med Care; 2006 May 10; 44(5 Suppl):I27-35. PubMed ID: 16625061
    [Abstract] [Full Text] [Related]

  • 9. Washington State CARE Project: downstream cost changes associated with the provision of cognitive services by pharmacists.
    Smith DH, Fassett WE, Christensen DB.
    J Am Pharm Assoc (Wash); 1999 May 10; 39(5):650-7. PubMed ID: 10533346
    [Abstract] [Full Text] [Related]

  • 10. Outpatient prescription drug utilization and expenditure patterns of noninstitutionalized aged Medicare beneficiaries.
    LaVange LM, Silverman HA.
    Natl Med Care Util Expend Surv B; 1987 Apr 10; (12):1-43. PubMed ID: 10313516
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. How does Cash and Counseling affect costs?
    Dale SB, Brown RS.
    Health Serv Res; 2007 Feb 10; 42(1 Pt 2):488-509. PubMed ID: 17244294
    [Abstract] [Full Text] [Related]

  • 13. Copayment for pharmaceutical services in a Medicaid program.
    Nelson AA, Quick MR.
    Contemp Pharm Pract; 1980 Feb 10; 3(1):37-42. PubMed ID: 10297666
    [Abstract] [Full Text] [Related]

  • 14. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit.
    Fischer MA, Avorn J.
    Pharmacoepidemiol Drug Saf; 2004 Apr 10; 13(4):207-14. PubMed ID: 15255087
    [Abstract] [Full Text] [Related]

  • 15. Medicare: looking for pareto optimal changes.
    Christensen S.
    Inquiry; 1992 Apr 10; 29(4):426-39. PubMed ID: 1473866
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.